Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX) is a molecular diagnostics company focused on developing and commercializing cancer detection tests. Their key products include DetermaRx for early-stage lung adenocarcinoma and DetermaIO, a gene expression assay.
Company Overview
Insight Molecular Diagnostics (IMDX) pioneers cancer detection through innovative molecular tests like DetermaRx and DetermaIO, offering early-stage diagnostics and personalized medicine solutions in a high-growth biotechnology market, despite current unprofitability, positioning them for significant future gains.
Investment Thesis
Investing in Insight Molecular Diagnostics (IMDX) presents a compelling opportunity due to its focus on innovative cancer diagnostics and strategic partnerships. While currently unprofitable with a P/E ratio of -3.86 and a negative profit margin of -1380.7%, the company's high gross margin of 54.7% indicates potential for future profitability as revenue scales. Key to IMDX's growth is the increasing adoption of its DetermaRx and DetermaIO tests, driven by the rising demand for early cancer detection and personalized medicine. The collaboration with Life Technologies further strengthens IMDX's market position by enhancing the accessibility of its assays. The company's relatively small market cap of $0.21 billion suggests significant upside potential if it can successfully commercialize its products and achieve profitability.
Key Highlights
- Market Cap of $0.21 billion indicates potential for growth as the company scales its operations and commercializes its diagnostic tests.
- Gross Margin of 54.7% demonstrates the company's ability to generate revenue efficiently from its products.
- P/E Ratio of -3.86 reflects current unprofitability but also highlights the potential for significant earnings growth in the future.
- Profit Margin of -1380.7% indicates substantial losses, emphasizing the need for improved cost management and revenue generation.
- Beta of 1.35 suggests the stock is more volatile than the market, offering potential for higher returns but also greater risk.
Competitors
Strengths
- Proprietary DetermaRx and DetermaIO assays.
- Expertise in molecular diagnostics and biomarker discovery.
- Collaboration with Life Technologies.
- Established relationships with key opinion leaders.
Weaknesses
- Current unprofitability and negative profit margin.
- Limited market share compared to larger competitors.
- Reliance on a small number of products.
- High beta indicating greater stock volatility.
Catalysts
- Ongoing: Increasing adoption of DetermaRx and DetermaIO by oncologists and pulmonologists.
- Ongoing: Expansion of strategic partnerships with hospitals and diagnostic centers.
- Upcoming: Publication of clinical data demonstrating the utility of DetermaIO in predicting immunotherapy response.
- Ongoing: Commercialization of Oncomine Comprehensive Assay Plus and DetermaIO assay through the Life Technologies collaboration.
- Upcoming: Regulatory approvals for new diagnostic assays in key markets.
Risks
- Ongoing: Competition from larger diagnostic companies with greater resources.
- Potential: Failure to achieve profitability and positive cash flow.
- Potential: Technological obsolescence of existing assays.
- Potential: Regulatory challenges and reimbursement issues.
- Ongoing: Dependence on key partnerships and collaborations.
Growth Opportunities
- Expansion of DetermaRx Market Reach: DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, presents a significant growth opportunity. The global lung cancer diagnostics market is projected to reach $8.1 billion by 2028. By expanding its sales and marketing efforts, IMDX can increase the adoption of DetermaRx among oncologists and pulmonologists, driving revenue growth. This expansion includes strategic partnerships with hospitals and diagnostic centers to broaden market penetration.
- Increased Adoption of DetermaIO: DetermaIO, a proprietary gene expression assay, offers another avenue for growth. As personalized medicine gains traction, the demand for gene expression assays in immuno-oncology is expected to rise. IMDX can capitalize on this trend by demonstrating the clinical utility of DetermaIO in predicting patient response to immunotherapy. This includes publishing clinical data and collaborating with key opinion leaders to promote its use.
- Strategic Partnerships and Collaborations: IMDX's collaboration with Life Technologies Corporation to develop and commercialize Oncomine Comprehensive Assay Plus and DetermaIO assay for use with Ion Torrent Genexus integrated sequencer and purification system is a key growth driver. By forging similar partnerships with other diagnostic and pharmaceutical companies, IMDX can expand its product offerings and market reach. These partnerships can also provide access to new technologies and expertise.
- Geographic Expansion: Currently focused on the United States and international markets, IMDX has the opportunity to expand its geographic footprint. By targeting high-growth markets in Asia and Europe, IMDX can diversify its revenue streams and reduce its reliance on the US market. This expansion requires regulatory approvals and strategic alliances with local distributors and healthcare providers.
- Development of New Diagnostic Assays: IMDX can leverage its expertise in molecular diagnostics to develop new assays for other types of cancer. By expanding its product portfolio, IMDX can address a broader range of clinical needs and increase its revenue potential. This includes investing in research and development to identify novel biomarkers and develop innovative diagnostic tests.
Opportunities
- Expansion of DetermaRx and DetermaIO market reach.
- Development of new diagnostic assays for other cancers.
- Geographic expansion into high-growth markets.
- Strategic partnerships with diagnostic and pharmaceutical companies.
Threats
- Competition from larger and more established diagnostic companies.
- Regulatory hurdles and reimbursement challenges.
- Technological advancements that could render existing assays obsolete.
- Economic downturns that could reduce healthcare spending.
Competitive Advantages
- Proprietary molecular diagnostic tests (DetermaRx and DetermaIO).
- Expertise in biomarker discovery and assay development.
- Strategic collaborations with industry leaders like Life Technologies.
- Established relationships with key opinion leaders in oncology.
About
Insight Molecular Diagnostics Inc. (IMDX), formerly known as OncoCyte Corporation, was founded in 2009 and is based in Nashville, Tennessee. The company operates as a molecular diagnostics entity, dedicated to the research, development, and commercialization of advanced laboratory-developed tests aimed at detecting cancer. IMDX's portfolio includes DetermaRx, a molecular test designed for the early detection of adenocarcinoma in the lung, and DetermaIO, a proprietary gene expression assay used in immuno-oncology. Beyond its core product offerings, IMDX provides comprehensive biomarker discovery testing, assay design and development, and clinical trial support services. These services extend to pharmaceutical companies, where IMDX offers a range of biomarker tests tailored to specific research and development needs. A key strategic alliance for IMDX is its collaboration agreement with Life Technologies Corporation. This partnership focuses on the development and commercialization of the Oncomine Comprehensive Assay Plus and DetermaIO assay, specifically for use with the Ion Torrent Genexus integrated sequencer and purification system, enhancing the accessibility and efficiency of their diagnostic solutions.
What They Do
- Develop and commercialize molecular diagnostic tests for cancer detection.
- Offer DetermaRx, a test for early-stage adenocarcinoma of the lung.
- Provide DetermaIO, a gene expression assay for immuno-oncology.
- Conduct biomarker discovery testing.
- Design and develop assays for pharmaceutical companies.
- Offer clinical trial support services.
- Collaborate with Life Technologies on assay development and commercialization.
Business Model
- Develop and sell proprietary molecular diagnostic tests.
- Provide biomarker discovery and assay development services.
- Generate revenue through collaborations and partnerships.
- Offer clinical trial support to pharmaceutical companies.
Industry Context
Insight Molecular Diagnostics operates within the rapidly evolving biotechnology industry, specifically focusing on molecular diagnostics for cancer detection. The market is driven by increasing cancer incidence, advancements in genomic technologies, and the growing demand for personalized medicine. The competitive landscape includes companies like ARMP (Aramis Therapeutics), CCCC (C4 Therapeutics Inc), CDXS (Codexis Inc), CYBN (Cybin Inc), and IVVD (Invivyd Inc), each with its own focus within the broader biotechnology sector. IMDX differentiates itself through its proprietary DetermaRx and DetermaIO assays, targeting specific needs in early-stage lung adenocarcinoma and immuno-oncology.
Key Customers
- Oncologists and pulmonologists.
- Hospitals and diagnostic centers.
- Pharmaceutical companies.
- Research institutions.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $260,000 | -$11M | $0.00 |
| Q2 2025 | $518,000 | -$10M | $0.00 |
| Q1 2025 | $2M | -$7M | $0.00 |
| Q4 2024 | $1M | -$34M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Insight Molecular Diagnostics Inc. (IMDX) stock price: $7.47 (+0.31, +4.33%)
Why Bull
- •Recent insider buying suggests those in the know see value, hinting at potential upside.
- •The buzz in trading circles is that IMDX's innovative approach could disrupt their sector.
- •Despite market headwinds, the community's overall sentiment on IMDX remains optimistic.
- •Rumors of a potential partnership are circulating, boosting confidence in the company's future prospects.
Why Bear
- •Significant short interest indicates many believe IMDX is overvalued and due for a correction.
- •Chatter suggests the company's recent product launch hasn't met expectations, raising concerns.
- •Community sentiment reveals worries about increased competition eroding IMDX's market share.
- •Whispers of potential regulatory hurdles are casting a shadow over IMDX's long-term growth prospects.
Latest News
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Feb 11, 2026
-
Earnings Scheduled For November 10, 2025
benzinga · Nov 10, 2025
-
Earnings Scheduled For August 11, 2025
benzinga · Aug 11, 2025
Technical Analysis
Rationale
AI-generated technical analysis for IMDX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Insight Molecular Diagnostics Inc. (IMDX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for IMDX.
Make a Prediction
Set your price target for Insight Molecular Diagnostics Inc. (IMDX), choose a timeframe, and track your prediction accuracy.
Current price: $7.47
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMDX.
Price Targets
Wall Street price target analysis for IMDX.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 6/100
Revenue increased 25.1% YoY, reflecting moderate but steady business growth.
-
Gross Margin 8/100
Gross margin at 55.1% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates IMDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Insight Molecular Diagnostics Inc. do?
Insight Molecular Diagnostics Inc. (IMDX) is a molecular diagnostics company that focuses on researching, developing, and commercializing proprietary laboratory-developed tests for cancer detection. Their primary products include DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression assay used in immuno-oncology. The company also provides biomarker discovery testing, assay design and development, and clinical trial support services to pharmaceutical companies, contributing to advancements in personalized medicine and cancer treatment.
Is IMDX stock a good buy?
IMDX stock presents a speculative investment opportunity. While the company currently faces profitability challenges, indicated by a negative P/E ratio and profit margin, its high gross margin suggests potential for improvement as revenue scales. The increasing demand for early cancer detection and personalized medicine, coupled with strategic partnerships like the one with Life Technologies, could drive future growth. However, investors should carefully consider the risks associated with the company's financial performance and competitive landscape before investing.
What are the main risks for IMDX?
The main risks for IMDX include intense competition from larger, more established diagnostic companies, the potential for technological obsolescence of its existing assays, and regulatory and reimbursement challenges. The company's current unprofitability and dependence on key partnerships also pose significant risks. A failure to achieve profitability, secure regulatory approvals, or maintain its competitive edge could negatively impact the company's financial performance and stock price.
Is IMDX a good stock to buy?
Whether IMDX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the IMDX MoonshotScore?
The MoonshotScore for IMDX is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is IMDX data updated?
IMDX stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to IMDX is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for IMDX?
Growth catalysts for Insight Molecular Diagnostics Inc. (IMDX) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Insight Molecular Diagnostics Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are IMDX's main competitors?
Insight Molecular Diagnostics Inc. (IMDX) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether IMDX has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about IMDX?
Wall Street analyst coverage for IMDX includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is IMDX's market cap?
Market capitalization (market cap) for IMDX is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows IMDX's current market cap alongside enterprise value and other valuation metrics.
How has IMDX stock performed recently?
IMDX's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing IMDX's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in IMDX?
Key risk categories for IMDX include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures IMDX's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling IMDX?
Insider trading activity for IMDX tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is IMDX a good stock for beginners?
Insight Molecular Diagnostics Inc. (IMDX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is IMDX for first-time investors?
Every stock carries risk, including Insight Molecular Diagnostics Inc. (IMDX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like IMDX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information. Future performance is subject to market conditions and company-specific factors.